Therapy Areas: Devices
Ribon Therapeutics Names Reeve to the Company's Board of Directors
9 November 2020 - - US-based clinical-stage oncology company Ribon Therapeutics has appointed Emma Reeve to its board of directors, the company said.

Reeve will serve as chair of the audit committee.

Reeve is a distinguished industry veteran who brings over 20 years of global financial experience across pharmaceutical, medical device and bio-pharma companies.

She currently serves as chief financial officer at Constellation Pharmaceuticals and oversaw the company's transition to a public company in July 2018.

Prior to joining Constellation, she served as interim chief financial officer and corporate controller of Parexel International, a global biopharmaceutical services company, where she was responsible for all aspects of finance, investor relations, procurement and facilities and oversaw the financial aspects of a USD 5bn leveraged buy-out to take the company private.

Reeve previously served as chief financial officer of both Inotek and Aton Pharma, and held senior finance and operational positions at Bristol-Myers Squibb (NYSE: BMY), Merck (NYSE: MRK) and Novartis. She currently serves on the board of PTC Therapeutics.

Ribon Therapeutics is a clinical stage biotechnology company developing first-in-class therapeutics targeting novel enzyme families activated under cellular stress conditions that contribute to disease.

Its lead program is RBN-2397, a first-in-class PARP7 inhibitor in clinical development for the treatment of cancer. Ribon is located in Cambridge, Massachusetts.